Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin as first-line therapy for follicular lymphoma
NCT00772655Phase 2Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2007
- Primary completion
- Jun 2010
01
Overview
Phase 2, open-label trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by Charité – Universitätsmedizin Berlin. Status: unknown.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00772655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00772655.